Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

Rhea-AI Summary

Aeglea BioTherapeutics (NASDAQ: AGLE) has announced presentations at the SSIEM Annual Symposium 2022 in Freiburg, Germany, from August 30 to September 2. Key topics include dietary management strategies for Homocystinuria and new data from the PEACE Phase 3 trial regarding pegzilarginase for Arginase 1 Deficiency. Significant presentations are scheduled for August 31 and September 1, showcasing advances in treatments for rare metabolic diseases. Aeglea's product AGLE-177 is also under investigation for Homocystinuria and has received Rare Pediatric Disease Designation.

Positive

• Pegzilarginase achieved primary endpoint of arginine reduction in PEACE Phase 3 trial.
• AGLE-177 has received Rare Pediatric Disease Designation and is in an ongoing Phase 1/2 trial.
• Presentations at SSIEM could enhance visibility and interest in Aeglea's therapies.

Negative

• None.

AUSTIN, Texas, Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 – September 2. The presentations include perspectives on dietary management of Homocystinuria, which will be given as both an oral and poster presentation, as well as additional safety and efficacy data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency.

Homocystinuria Presentations:

Title: Dietary management of homocystinuria (HCU) caused by cystathionine beta-synthase (CBS) deficiency: Perspectives from a global cohort of metabolic dietitians
Abstract: SSIEM22-2306
Oral Presentation Time: August 31, 11:15 – 11:30 am CEST
Oral Presentation Session: SM23, SSIEM-DG Meeting
Poster Presentation Time: August 31, 6:45 – 8:15 pm CEST
Presenter: Danielle Starin, MS, RD, Children's National Hospital, Washington, DC

Pegzilarginase Presentations:

Oral Presentation

Title: Pegzilarginase efficacy in Arginase 1 Deficiency: Results of the PEACE pivotal phase 3 trial
Abstract: SSIEM22-2674
Presentation Time: September 1, 3:15 – 3:30 pm CEST
Session: PAS4A, Gene and Innovative Therapies
Presenter: Rossana Sanchez Russo, MD, Emory University School of Medicine, Atlanta, Georgia

Poster Presentation

Title: Safety and tolerability of pegzilarginase for Arginase 1 Deficiency in the PEACE pivotal phase 3 clinical trial
Abstract: SSIEM22-2687
Presentation Time: August 31, 6:45 – 8:15 pm CEST
Presenter: Rossana Sanchez Russo, MD, Emory University School of Medicine, Atlanta, Georgia

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea is investigating AGLE-177 in an ongoing Phase 1/2 clinical trial for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea's other clinical program, pegzilarginase, achieved the primary endpoint of arginine reduction in the PEACE Phase 3 clinical trial and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-presentations-at-the-society-for-the-study-of-inborn-errors-of-metabolism-ssiem-annual-symposium-2022-301614007.html

SOURCE Aeglea BioTherapeutics, Inc.

FAQ

What presentations did Aeglea BioTherapeutics announce at the SSIEM 2022 symposium?

Aeglea announced oral and poster presentations on dietary management of Homocystinuria and data from the PEACE Phase 3 trial for pegzilarginase.

When is Aeglea's presentation on pegzilarginase at the SSIEM symposium?

The pegzilarginase presentation is scheduled for September 1, 2022, from 3:15 to 3:30 pm CEST.

What are the key findings from the PEACE Phase 3 trial?

The PEACE Phase 3 trial achieved its primary endpoint of arginine reduction for pegzilarginase.

What is AGLE-177 and its current status?

AGLE-177 is under investigation in a Phase 1/2 clinical trial for the treatment of Homocystinuria and has received Rare Pediatric Disease Designation.